CardioComm Solutions, Inc.
TSX VENTURE : EKG

CardioComm Solutions, Inc.

February 03, 2012 14:30 ET

CardioComm Solutions, Inc. Issues Stock Options

TORONTO, ONTARIO--(Marketwire - Feb. 3, 2012) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") today announced that it has granted 100,000 incentive stock options to Mr. Simi Grossman, an independent member of the board of directors. The options are exercisable at $0.355 per share, based on markets prior day's close, for five years from the date of grant, are vested equally over 18 months at the end of each three month period from the date of grant and are subject to a four month hold period. The grant of options is subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

"Mr. Grosman is a senior member of CardioComm Solutions' C4 ("CardioComm Solutions Coordinating Centre") management team. He contributes to this important revenue generating service on an annual agreement of "options for service". This granting of options is related to his continuingly active role in managing the C4 sales force and contributing to market expansion planning," said Etienne Grima, CardioComm Solutions' CEO.

C4 is CardioComm Solutions' cardiac monitoring service which allows patients to have remote, telemedicine based ECG and cardiac arrhythmia monitoring while they go about their daily activities at home or at work. "We value Mr. Grosman's continued contributions as we continue to expand C4 subscription in Canada and look to expansion into the USA and overseas paired with the planned C4 integration of the physician prescribed HeartCheck™ ECG monitor and in the USA for the over the counter approved ("OTC") HeartCheck™ PEN."

About CardioComm Solutions, Inc.

CardioComm Solution's patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information